Short term impact of guidelines on vancomycin dosing and therapeutic drug monitoring

International Journal of Clinical Pharmacy

Volumn 34, Issue 2, 2012, Pages 282-285

  Swartling, Maria ^a   Gupta, Reetu ^b   Dudas, Vicky ^c   Guglielmo, B Joseph ^b  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Appropriate use; Education; Guidelines; TDM; Therapeutic drug monitoring; Vancomycin

Indexed keywords

VANCOMYCIN;

ABDOMINAL INFECTION; APPROPRIATE DRUG USE; ARTICLE; BACTEREMIA; BLOOD SAMPLING; CENTRAL NERVOUS SYSTEM INFECTION; DEMOGRAPHY; DOSE KIDNEY FUNCTION RELATION; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG USE; FEBRILE NEUTROPENIA; HUMAN; MAJOR CLINICAL STUDY; MEDICAL EDUCATION; MEDICAL STAFF; NOMOGRAM; NURSE; PATIENT SELECTION; PHLEBOTOMIST; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTHESIS INFECTION; PYREXIA IDIOPATHICA; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; SEPSIS; SKIN INFECTION; SOFT TISSUE INFECTION; STEADY STATE; URINARY TRACT INFECTION;

ACADEMIC MEDICAL CENTERS; ANTI-BACTERIAL AGENTS; DRUG MONITORING; DRUG UTILIZATION; EDUCATION, MEDICAL, CONTINUING; EDUCATION, NURSING, CONTINUING; EDUCATION, PHARMACY, CONTINUING; GUIDELINE ADHERENCE; HEALTH PERSONNEL; HUMANS; NOMOGRAMS; PHARMACY SERVICE, HOSPITAL; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES; SAN FRANCISCO; TIME FACTORS; VANCOMYCIN;

EID: 84862881888     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-012-9614-6     Document Type: Article

References (9)

1. Grundmann H, Aires-de-Sousa M, Boyce J, Tiemersma E. Emergence and resurgence of methicillin-resistant Staphylococcus aureus as a public-health threat. Lancet. 2006;368(9538):874-85.
2. Liu C, Graber CJ, Karr M, Diep BA, Basuino L, Schwartz BS, et al. A population-based study of the incidence and molecular epidemiology of methicillin-resistant Staphylococcus aureus disease in San Francisco, 2004-2005. Clin Infect Dis. 2008;46(11): 1637-46.
3. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis. 2008;46(Suppl 5):S360-7.
4. Tacconelli E. Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Curr Opin Infect Dis. 2009;22(4):352-8.
5. Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American society of health-system pharmacists, the infectious diseases society of America, and the society of infectious diseases pharmacists. Am J Health-Syst Pharm. 2009;66(1):82-98.
6. Hall RG II, Payne KD, Bain AM, Rahman AP, Nguyen ST, Eaton SA, et al. Multicenter evaluation of vancomycin dosing: emphasis on obesity. Am J Med. 2008;121(6):515-8.
7. de Castro MS, Kopittke L, Fuchs FD, Tannhauser M. Evidence of inappropriate use of vancomycin in a university affiliated hospital in Brazil. Pharmacoepidemiol Drug Saf. 1999;8(6):405-11.
8. Rodman DP, McKnight JT, Rogers T, Robbins M. The appropriateness of initial vancomycin dosing. J Fam Pract. 1994;38(5): 473-7.
9. Carroll DJ, Austin GE, Stajich GV, Miyahara RK, Murphy JE, Ward ES. Effect of education on the appropriateness of serum drug concentration determination. Ther Drug Monit. 1992;14(1):81-4.